Understanding the New Nationwide Study on RTIs and AMR

A groundbreaking 12-year analysis has shed light on the shifting patterns of respiratory tract infections (RTIs) and antimicrobial resistance (AMR) across the United Arab Emirates (UAE), drawing from the country's comprehensive national surveillance system. Published in the International Journal of Infectious Diseases in January 2026, this retrospective study examined data from 2010 to 2022, covering over 137,000 RTI cases reported from 345 healthcare facilities nationwide. Researchers, including experts from Khalifa University and the UAE University, highlight how lower respiratory tract infections (LRIs) dominate, comprising 73.1% of cases, with significant rises in certain regions and pathogens. This work is crucial for public health professionals navigating UAE's diverse expatriate population and high mobility, factors that amplify infection risks.

The UAE's National AMR Surveillance Network, initiated in Abu Dhabi and expanded nationwide, provides a robust dataset aligned with WHO GLASS standards. By tracking pathogen distribution and resistance profiles, the study reveals actionable insights into how RTIs have evolved amid global challenges like COVID-19. For academics and researchers interested in infectious disease epidemiology, this underscores opportunities in higher-ed research jobs focused on AMR surveillance.

Methodology: A Comprehensive Nationwide Dataset

The study employed a retrospective observational approach, analyzing all microbiologically confirmed RTI cases from 2010 to 2022. Data came from 317 surveillance sites and 45 laboratories, using standardized identification via MALDI-TOF MS and susceptibility testing per CLSI guidelines with tools like VITEK 2 and BD Phoenix. Specimens were categorized as upper RTIs (nasal, throat swabs) or lower (sputum, bronchoalveolar lavage), excluding duplicates and focusing on key bacteria, fungi, and Mycobacterium tuberculosis.

Incidence rates were calculated per 100,000 population, adjusted for demographic shifts, with trends assessed via Joinpoint regression for annual percent change (AAPC). Multidrug resistance (MDR) was defined as non-susceptibility to at least three antimicrobial classes. This rigorous methodology ensures reliability, reflecting UAE's proactive AMR monitoring since 2010.

Patient demographics revealed 36.6% Emiratis and 63.4% expatriates from 175 nationalities, with higher ICU admissions (21.8%) and mortality (16.3%) in LRI cases, emphasizing the clinical burden.

Epidemiological Trends: Rising LRI Incidence Post-2015

Over the study period, LRIs accounted for the bulk of cases at 73.1% (100,856 isolates), versus 26.9% URIs. Incidence remained stable from 2011-2014 but surged significantly from 2015-2022 (AAPC 1.58%, 95% CI 1.58-3.87), driven by population growth, improved diagnostics, and post-pandemic effects. Notably, Northern Emirates saw a steeper rise (AAPC 11.03%), contrasting stability in Abu Dhabi and Dubai.

Pathogen shifts included declines in Acinetobacter baumannii, Escherichia coli, and Haemophilus influenzae, but increases in Candida albicans, signaling emerging fungal threats. Tuberculosis cases (6,416) rose post-2020 (AAPC 18.91%), largely among expatriates. These trends mirror global patterns but are UAE-specific due to migration.

Such dynamics call for enhanced training in research careers in epidemiology.

Dominant Pathogens: Hospital-Associated Gram-Negatives Lead

In LRIs, Gram-negative bacteria dominated: Pseudomonas aeruginosa (18.6%), Klebsiella pneumoniae (16.8%), Escherichia coli (5.6%), Stenotrophomonas maltophilia (4.7%), Acinetobacter baumannii (4.6%). Gram-positives like Staphylococcus aureus (12.7%) and Streptococcus pneumoniae (4.7%) followed, with Haemophilus influenzae at 4.1% and fungi like Candida albicans at 3.5%.

• P. aeruginosa: Most common, linked to ventilator-associated pneumonia.
• K. pneumoniae: High in ICU settings.
• S. aureus: Community and hospital strains prevalent.

URI profiles showed higher susceptibility, with over 85% non-MDR for most pathogens. This distribution reflects UAE's hospital-centric reporting and expatriate-driven community transmission.

Regional Disparities: Northern Emirates Under Spotlight

Abu Dhabi reported 55.7% of cases (median age 38), Dubai 22% (age 33), Northern Emirates 22.3% (age 56). Incidence rose sharply in the north, possibly due to demographics, healthcare access, and migration patterns. AMR varied: higher carbapenem resistance in certain emirates tied to population density and travel hubs like Dubai.

These insights advocate for decentralized surveillance, with Northern Emirates needing bolstered resources. For public health experts eyeing UAE roles, check UAE academic opportunities.

Photo by Amanda Jones on Unsplash

AMR Profiles in Gram-Negative Pathogens

Gram-negatives posed the gravest AMR threats. Enterobacterales showed 22.5% carbapenem resistance (14.4% in K. pneumoniae) and 30.1% third-generation cephalosporin (3GC) resistance (62.3% E. coli). A. baumannii hit 61% carbapenem resistance, with 22.8% extensively drug-resistant (XDR). P. aeruginosa carbapenem resistance was 27.4%, though declining.

Trends: Declines in A. baumannii and P. aeruginosa resistance suggest stewardship gains, but persistent high rates limit empiric options like piperacillin-tazobactam.

Gram-Positives, Fungi, and Emerging Resistances

S. pneumoniae macrolide resistance reached 56.9%, rising significantly. S. pyogenes showed 55.2% macrolide resistance. MRSA resistance increased, challenging community treatments. Fungal C. albicans incidence rose, with potential azole resistance needing monitoring. Vancomycin resistance remained low (10.3% in enterococci).

These shifts demand updated guidelines and rapid diagnostics.

Tuberculosis: Post-COVID Surge Among Expatriates

Of 6,416 TB cases (all LRI), 85% affected South Asian and East African expatriates, with a post-2020 surge (AAPC 18.91%). Drug resistance stayed low (<15%, MDR <5%), but disruptions in screening fueled rises. This highlights migration's role in UAE TB epidemiology, urging targeted screening.

Drivers of AMR and UAE-Specific Challenges

UAE's expatriate-heavy (88% population), mobile society imports resistant strains from high-burden areas. Overuse in hospitals, COVID-era antibiotics, and variable stewardship contribute. Global comparisons show UAE's rates exceed some MENA peers but trail hotspots like India. Improved diagnostics post-2015 boosted reporting.

Stakeholders: MOHAP leads surveillance; universities like Khalifa drive research.

Policy Recommendations and Stewardship Strategies

Key calls: Region-tailored controls, real-time genomic surveillance for XDR clones, fungal diagnostics in ICUs, revised empiric therapies, TB migrant screening. Align with UAE NAP-AMR 2025-2031, emphasizing stewardship and awareness.

Photo by David Trinks on Unsplash

• Enhance Northern Emirates capacity.
• Digital TB tracking for expatriates.
• Evaluate novel antibiotics.

Future Outlook: Research and Innovation Needs

Prospects include AI-driven prediction, vaccine rollouts (pneumococcal), and phage therapy trials. UAE universities are pivotal, with rising outputs in AMR genomics. Global collaboration via WHO GLASS will aid. For careers, faculty positions in infectious diseases abound.

Implications for Healthcare and Academia

This study positions UAE as a surveillance leader, informing NAP updates. It stresses multidisciplinary approaches: clinicians, researchers, policymakers. Aspiring professionals can leverage platforms like Rate My Professor for insights or pursue higher-ed jobs in public health. Explore career advice and university jobs to contribute to UAE's AMR fight. Share your views in comments below.